Skip to main content
SIU Annual Conference Main banner
 
Presentation Icons
Surgery Day
Surgery Day
Bench-to-Bedside
Bench-to-Bedside
SIU@U
SIU@U
    Session Type: B2B

    7th B2B Uro-Oncology: GU Cancers Triad Meeting - KIDNEY CANCER

    Friday, October 31, 2025
    12:45 - 14:25 GMT+0

    Bench-to-Bedside SIU@U

    This educational programme is supported by:
    B2B Presenting Sponsors: Daiichi-Sankyo | AstraZeneca, Johnson & Johnson
    B2B Contributing Sponsors: Bristol Myers Squibb, CG Oncology, Ferring Pharmaceuticals, Merck Sharp & Dohme LLC, Novartis AG

    B2B Scientific Programme Committee: Peter Black, Canada / Caroline Moore, United Kingdom / Simon Tanguay, Canada

    Learning Objectives :

    At the end of this session, attendees should be able to:
    • Evaluate the benefits, risks, and limitations of various treatment options across the management continuum in prostate cancer, bladder cancer, and kidney cancer.
    • Recognize the role of imaging and genetic markers in guiding treatment decision-making.
    • Analyze the efficacy and safety of emerging therapeutic approaches for the management of GU cancers based on current clinical data.
    • Recall strategies to identify, manage, and mitigate adverse events related to systemic treatment.
    • Discuss the importance of personalized medicine, based on treatment costs and patient preference, while minimizing toxicity and maximizing efficacy.

    Presentations:

    • 12:45 - 13:00 GMT+0
      IO Rechallenge After Adjuvant IO

      Speaker: Viktor Gruenwald – University Hospital Essen

    • 13:00 - 13:15 GMT+0
      Cytoreductive Nephrectomy in the Era of IO

      Speaker: Arnaud Méjean – Université Paris-Cité, HEGP, APHP

    • 13:15 GMT+0
      Debate: Should Oligometastatic RCC Be Treated by Surgery or SBRT?

      Moderator: Simon Tanguay – McGill University

    • 13:15 - 13:23 GMT+0
      Surgery

      Speaker: Axel Bex – University College London

    • 13:23 - 13:31 GMT+0
      SBRT

      Speaker: Amy Clifford – Royal Free Hospital, London

    • 13:31 - 13:40 GMT+0
      Discussion and Q&A

      Speaker: Axel Bex – University College London

      Speaker: Amy Clifford – Royal Free Hospital, London

      Moderator: Simon Tanguay – McGill University

    • 13:40 - 14:10 GMT+0
      Panel Discussion: Systemic therapy combination in metastatic RCC

      Panelist: Christian Kollmannsberger – BC Cancer Vancouver / University of British Columbia

      Moderator: Simon Tanguay – McGill University

      Panelist: Viktor Gruenwald – University Hospital Essen

    • 14:10 - 14:25 GMT+0
      Belzutifan in Metastatic Clear Cell RCC

      Speaker: Christian Kollmannsberger – BC Cancer Vancouver / University of British Columbia